These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 17405897)

  • 1. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
    Sequist LV
    Oncologist; 2007 Mar; 12(3):325-30. PubMed ID: 17405897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An update on molecularly targeted therapies in second- and third-line treatment in non-small cell lung cancer: focus on EGFR inhibitors and anti-angiogenic agents.
    Majem M; Pallarès C
    Clin Transl Oncol; 2013 May; 15(5):343-57. PubMed ID: 23359171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical studies with non-iressa EGFR tyrosine kinase inhibitors.
    Bonomi P
    Lung Cancer; 2003 Aug; 41 Suppl 1():S43-8. PubMed ID: 12867061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.
    Ready N
    Semin Oncol; 2005 Apr; 32(2 Suppl 3):S35-41. PubMed ID: 16015534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II data with ZD6474, a small-molecule kinase inhibitor of epidermal growth factor receptor and vascular endothelial growth factor receptor, in previously treated advanced non-small-cell lung cancer.
    Lee D
    Clin Lung Cancer; 2005 Sep; 7(2):89-91. PubMed ID: 16179094
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations?
    Tartarone A; Lerose R; Lazzari C; Gregorc V; Aieta M
    Med Oncol; 2014 Aug; 31(8):78. PubMed ID: 24958518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second-generation epidermal growth factor tyrosine kinase inhibitors in non-small cell lung cancer.
    Mukherji D; Spicer J
    Expert Opin Investig Drugs; 2009 Mar; 18(3):293-301. PubMed ID: 19243280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model.
    Matsumori Y; Yano S; Goto H; Nakataki E; Wedge SR; Ryan AJ; Sone S
    Oncol Res; 2006; 16(1):15-26. PubMed ID: 16783964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New insights in drug development for the non-small cell lung cancer therapy.
    Gridelli C; Rossi A; Maione P; Ferrara C; Del Gaizo F; Guerriero C; Nicolella D; Palazzolo G; Falanga M; Colantuoni G
    Front Biosci; 2008 May; 13():5108-19. PubMed ID: 18508573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor.
    Harichand-Herdt S; Ramalingam SS
    Semin Thorac Cardiovasc Surg; 2008; 20(3):217-23. PubMed ID: 19038731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent developments related to the EGFR as a target for cancer chemotherapy.
    Speake G; Holloway B; Costello G
    Curr Opin Pharmacol; 2005 Aug; 5(4):343-9. PubMed ID: 15950538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Research progress on resistance mechanisms of epidermal growth factor receptor
tyrosine kinase inhibitors in non-small cell lung cancer].
    Li Y; Song L
    Zhongguo Fei Ai Za Zhi; 2012 Feb; 15(2):106-11. PubMed ID: 22336239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Select clinical trials of erlotinib (OSI-774) in non-small-cell lung cancer with emphasis on phase III outcomes.
    Fuster LM; Sandler AB
    Clin Lung Cancer; 2004 Dec; 6 Suppl 1():S24-9. PubMed ID: 15638954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and safety of EGFR inhibitor monotherapy in non-small cell lung cancer: a systematic review.
    Yang X; Yang K; Kuang K
    Curr Oncol Rep; 2014 Jun; 16(6):390. PubMed ID: 24807015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three generations of epidermal growth factor receptor tyrosine kinase inhibitors developed to revolutionize the therapy of lung cancer.
    Zhang H
    Drug Des Devel Ther; 2016; 10():3867-3872. PubMed ID: 27920501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal management of patients with non-small cell lung cancer and epidermal growth factor receptor mutations.
    Lin CC; Yang JC
    Drugs; 2011 Jan; 71(1):79-88. PubMed ID: 21175241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidermal growth factor receptor tyrosine kinase inhibitors: application in non-small cell lung cancer.
    Thomas M
    Cancer Nurs; 2003 Dec; 26(6 Suppl):21S-25S. PubMed ID: 15025409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Next-Generation EGFR-TKIs in Patients With Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.
    Qi YT; Hou Y; Qi LC
    Technol Cancer Res Treat; 2020; 19():1533033820940426. PubMed ID: 32723164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.